ERBB2 and breast cancer: Next, the molecular subtype distribution was derived from the North American Association of Central Cancer Registries (NAACCR), namely 73.0% of cases with both HR+ and Her-, and 15.0% of patients with Her2+ breast cancer irrespective of HR status (NAACCR, 2019).